{"filing":{"accession_number":"0001628280-26-045569","cik":"0001649904","ticker":"RYTM","company_name":"RHYTHM PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"rytm-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026045569/rytm-20260624.htm"},"events":[{"id":13971,"run_id":12422,"accession_number":"0001628280-26-045569","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Rhythm Pharmaceuticals' Annual Meeting of Stockholders held on June 24, 2026. The filing presents voting outcomes for three proposals: election of two Class III Directors (David W. J. McGirr and David P. Meeker, MD), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed. Shareholder votes on director elections and auditor ratification are material governance events affecting investor assessment of board composition and audit oversight.","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11268,"accession_number":"0001628280-26-045569","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Rhythm Pharmaceuticals' Annual Meeting of Stockholders held on June 24, 2026. The filing presents voting outcomes for three proposals: election of two Class III Directors (David W. J. McGirr and David P. Meeker, MD), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed. Shareholder votes on director elections and auditor ratification are material governance events affecting investor assessment of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:47:36.312669+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11268,"accession_number":"0001628280-26-045569","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Rhythm Pharmaceuticals' Annual Meeting of Stockholders held on June 24, 2026. The filing presents voting outcomes for three proposals: election of two Class III Directors (David W. J. McGirr and David P. Meeker, MD), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed. Shareholder votes on director elections and auditor ratification are material governance events affecting investor assessment of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:47:36.312669+00:00","company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","filing_date":"2026-06-25"}]}